Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Cystic Fibrosis Foundation and European Cystic Fibrosis Society Survey of cystic fibrosis mental health care delivery J. Abbott, J.S. Elborn, A.M. Georgiopoulos,

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients Karen.

Abaigeal D. Jackson, Christopher H. Goss Journal of Cystic Fibrosis

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint D.R. VanDevanter, A. Yegin, W.J. Morgan,

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

David N. Sheppard Journal of Cystic Fibrosis

The ease of breathing test tracks clinical changes in cystic fibrosis

Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study Matthew N. Hurley, Tricia M. McKeever,

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Cynthia M. Ward, Tara Brinkman, Keith J. Slifer, Shruti M. Paranjape

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial S.K. Kabra, R. Pawaiya, Rakesh Lodha,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

A.H. Gifford Journal of Cystic Fibrosis

M. Wouthuyzen-Bakker, F.A.J.A. Bodewes, H.J. Verkade

Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects Warren Lenney, Frank Edenborough,

Demographics of glucose metabolism in cystic fibrosis

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Michael D. Parkins, R. Andres Floto Journal of Cystic Fibrosis

Disease disclosure in individuals with cystic fibrosis: Association with psychosocial and health outcomes Adrienne P. Borschuk, Robin S. Everhart, Michelle.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients Gregory S. Sawicki, Will Chou, Karina.

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Beta-lactam allergy in adults with cystic fibrosis

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Absence of a gender gap in survival

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Respiratory physicians and clinic coordinators' attitudes to population-based cystic fibrosis carrier screening Fiona Cunningham, Sharon Lewis, Lisette.

Presentation transcript:

Cystic fibrosis patient registries: A valuable source for clinical research Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis Volume 17, Issue 4, Pages 433-440 (July 2018) DOI: 10.1016/j.jcf.2018.03.001 Copyright © 2018 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Two sample patients from a patient registry where indication for treatment is related to the risk of a future health outcome. This is in contrast to a randomized controlled trial where treatment is randomly assigned. Journal of Cystic Fibrosis 2018 17, 433-440DOI: (10.1016/j.jcf.2018.03.001) Copyright © 2018 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Sample CF Patient Registry that includes the population of patients on single inhaled antibiotic (dark shapes) and those on continuous alternating inhaled antibiotics (light shapes). The variety of the shape sizes reflects the variation in clinical characteristics between individual subjects in the registry. After the propensity scores are generated and patients are matched, the study cohort is created. Patients who cannot be matched (outside of the rectangle) are excluded. Source: Adapted from Moss R R et al. Circulation. 2003;108:II-90-II-97. Journal of Cystic Fibrosis 2018 17, 433-440DOI: (10.1016/j.jcf.2018.03.001) Copyright © 2018 European Cystic Fibrosis Society Terms and Conditions